Protocol Ledger

NCT05334823 · Phase II · RECRUITING

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Interventional Phase II clinical trial protocol NCT05334823 sponsored by Chongqing Precision Biotech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-01-26 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05334823
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05334823
Protocol FieldVerified Registry Value
NCT IdentifierNCT05334823
Consolidated Lead SponsorChongqing Precision Biotech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2022-01-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05334823
Hospital Research SiteLocationSite Profile
Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Jiangsu Province HospitalNanjing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI